AG
KRYS icon

Artal Group’s Krystal Biotech KRYS Stock Holding History

Artal Group’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-349,669
Closed -$41.1M – 110
2023
Q2 		$41.1M Sell
349,669
-62,413
-15% -$6.37M 1.27% 15
2023
Q1 		$33M Buy
412,082
+12,082
+3% +$949K 1.96% 15
2022
Q4 		$31.7M Sell
400,000
-100,000
-20% -$7.42M 1.77% 15
2022
Q3 		$34.9M Hold
500,000
– – 1.49% 21
2022
Q2 		$32.8M Hold
500,000
– – 1.75% 18
2022
Q1 		$33.3M Sell
500,000
-200,000
-29% -$12.5M 1.39% 18
2021
Q4 		$49M Buy
700,000
+200,000
+40% +$11.6M 1.33% 20
2021
Q3 		$26.1M Hold
500,000
– – 0.58% 43
2021
Q2 		$34M Hold
500,000
– – 0.69% 32
2021
Q1 		$38.5M Buy
500,000
+262,500
+111% +$19.1M 0.68% 33
2020
Q4 		$14.3M Hold
237,500
– – 0.31% 75
2020
Q3 		$10.2M Buy
237,500
+37,500
+19% +$1.63M 0.25% 77
2020
Q2 		$8.28M Buy
200,000
+100,000
+100% +$4.81M 0.23% 77
2020
Q1 		$4.32M Buy
100,000
+20,000
+25% +$1.05M 0.18% 78
2019
Q4 		$4.43M Sell
80,000
-70,000
-47% -$3.43M 0.17% 77
2019
Q3 		$5.21M Sell
150,000
-150,000
-50% -$6.71M 0.21% 70
2019
Q2 		$12.1M Hold
300,000
– – 0.49% 44
2019
Q1 		$9.87M Buy
300,000
+25,000
+9% +$589K 0.4% 51
2018
Q4 		$5.71M Buy
275,000
+125,000
+83% +$2.62M 0.21% 66
2018
Q3 		$2.64M Hold
150,000
– – 0.07% 93
2018
Q2 		$2.23M Hold
150,000
– – 0.05% 92
2018
Q1 		$1.51M Hold
150,000
– – 0.02% 98
2017
Q4 		$1.58M Buy
150,000
+50,000
+50% +$501K 0.02% 102
2017
Q3 		$997K Buy
+100,000
New +$1.01M 0.02% 107

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Artal Group's KRYS Position: Q3 2023 in Review

Artal Group sold out of Krystal Biotech (KRYS) in Q3 2023, closing a stake of 349,669 shares — an estimated $41.1M sold.

Artal Group first reported a position in KRYS in Q3 2017 and held it in 24 quarters. The position peaked at $49M in Q4 2021. 188 funds tracked by Wall St. Rank hold KRYS as of Q3 2023.

  • Artal Group reported no remaining Krystal Biotech position as of Q3 2023 after selling out during the quarter.
  • Artal Group sold 349,669 Krystal Biotech shares in Q3 2023, an estimated $41.1M.
  • Artal Group first reported a position in Krystal Biotech in Q3 2017 and held it in 24 quarters.
  • Artal Group's Krystal Biotech position peaked at $49M in Q4 2021.
  • 188 funds tracked by Wall St. Rank held Krystal Biotech as of Q3 2023.

Based on Artal Group's 13F filing for Q3 2023, filed 13 Nov 2023.